We found elevated reactive gliosis and FN1 deposition in APOEε4/4 carriers with AD compared to APOEε3/3 controls (ANOVA adjusted P = 1.5E−02 for GFAP intensity, 4.1E-11 for FN1 intensity) (Fig. 6). This evidence concerns the gene FN1 and Alzheimer disease.